Free Trial
→ Read this warning immediately (From Porter & Company) (Ad)tc pixel Free MPLT Stock Alerts

Maplight Therapeutics (MPLT) Competitors

Maplight Therapeutics logo
$29.46 +1.45 (+5.18%)
Closing price 04:00 PM Eastern
Extended Trading
$29.43 -0.03 (-0.10%)
As of 05:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

MPLT vs. NNNN, DNTH, TWST, ERAS, and INDV

Should you buy Maplight Therapeutics stock or one of its competitors? MarketBeat compares Maplight Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Maplight Therapeutics include Anbio Biotechnology (NNNN), Dianthus Therapeutics (DNTH), Twist Bioscience (TWST), Erasca (ERAS), and Indivior (INDV). These companies are all part of the "pharmaceutical products" industry.

How does Maplight Therapeutics compare to Anbio Biotechnology?

Anbio Biotechnology (NASDAQ:NNNN) and Maplight Therapeutics (NASDAQ:MPLT) are both manufacturing companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation.

Maplight Therapeutics has a consensus target price of $37.78, indicating a potential upside of 28.23%. Given Maplight Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Maplight Therapeutics is more favorable than Anbio Biotechnology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Anbio Biotechnology
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Maplight Therapeutics
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
3 Strong Buy rating(s)
3.00

Anbio Biotechnology has higher revenue and earnings than Maplight Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Anbio Biotechnology$8.65M286.45$6.40MN/AN/A
Maplight TherapeuticsN/AN/A-$161.15M-$40.99N/A

In the previous week, Anbio Biotechnology's average media sentiment score of 1.11 beat Maplight Therapeutics' score of -0.63 indicating that Anbio Biotechnology is being referred to more favorably in the media.

Company Overall Sentiment
Anbio Biotechnology Positive
Maplight Therapeutics Negative

Company Net Margins Return on Equity Return on Assets
Anbio BiotechnologyN/A N/A N/A
Maplight Therapeutics N/A N/A N/A

Summary

Maplight Therapeutics beats Anbio Biotechnology on 4 of the 7 factors compared between the two stocks.

How does Maplight Therapeutics compare to Dianthus Therapeutics?

Dianthus Therapeutics (NASDAQ:DNTH) and Maplight Therapeutics (NASDAQ:MPLT) are both pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Dianthus Therapeutics presently has a consensus target price of $117.82, indicating a potential upside of 45.06%. Maplight Therapeutics has a consensus target price of $37.78, indicating a potential upside of 28.23%. Given Dianthus Therapeutics' higher possible upside, analysts plainly believe Dianthus Therapeutics is more favorable than Maplight Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dianthus Therapeutics
1 Sell rating(s)
0 Hold rating(s)
11 Buy rating(s)
2 Strong Buy rating(s)
3.00
Maplight Therapeutics
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
3 Strong Buy rating(s)
3.00

Maplight Therapeutics has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -12,998.50%. Maplight Therapeutics' return on equity of 0.00% beat Dianthus Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Dianthus Therapeutics-12,998.50% -27.30% -25.91%
Maplight Therapeutics N/A N/A N/A

47.5% of Dianthus Therapeutics shares are held by institutional investors. 3.0% of Dianthus Therapeutics shares are held by insiders. Comparatively, 3.8% of Maplight Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Maplight Therapeutics has lower revenue, but higher earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dianthus Therapeutics$2.04M2,176.62-$162.34M-$4.13N/A
Maplight TherapeuticsN/AN/A-$161.15M-$40.99N/A

In the previous week, Dianthus Therapeutics had 7 more articles in the media than Maplight Therapeutics. MarketBeat recorded 7 mentions for Dianthus Therapeutics and 0 mentions for Maplight Therapeutics. Dianthus Therapeutics' average media sentiment score of 0.50 beat Maplight Therapeutics' score of -0.63 indicating that Dianthus Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Dianthus Therapeutics Neutral
Maplight Therapeutics Negative

Summary

Dianthus Therapeutics and Maplight Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Maplight Therapeutics compare to Twist Bioscience?

Twist Bioscience (NASDAQ:TWST) and Maplight Therapeutics (NASDAQ:MPLT) are both pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and media sentiment.

Twist Bioscience has higher revenue and earnings than Maplight Therapeutics. Twist Bioscience is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Twist Bioscience$376.57M11.58-$77.67M-$1.33N/A
Maplight TherapeuticsN/AN/A-$161.15M-$40.99N/A

Maplight Therapeutics has a net margin of 0.00% compared to Twist Bioscience's net margin of -19.85%. Maplight Therapeutics' return on equity of 0.00% beat Twist Bioscience's return on equity.

Company Net Margins Return on Equity Return on Assets
Twist Bioscience-19.85% -26.73% -19.15%
Maplight Therapeutics N/A N/A N/A

Twist Bioscience currently has a consensus price target of $58.00, indicating a potential downside of 17.19%. Maplight Therapeutics has a consensus price target of $37.78, indicating a potential upside of 28.23%. Given Maplight Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Maplight Therapeutics is more favorable than Twist Bioscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Twist Bioscience
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.75
Maplight Therapeutics
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
3 Strong Buy rating(s)
3.00

In the previous week, Twist Bioscience had 6 more articles in the media than Maplight Therapeutics. MarketBeat recorded 6 mentions for Twist Bioscience and 0 mentions for Maplight Therapeutics. Twist Bioscience's average media sentiment score of 1.16 beat Maplight Therapeutics' score of -0.63 indicating that Twist Bioscience is being referred to more favorably in the media.

Company Overall Sentiment
Twist Bioscience Positive
Maplight Therapeutics Negative

Summary

Maplight Therapeutics beats Twist Bioscience on 8 of the 13 factors compared between the two stocks.

How does Maplight Therapeutics compare to Erasca?

Maplight Therapeutics (NASDAQ:MPLT) and Erasca (NASDAQ:ERAS) are both pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability.

Maplight Therapeutics currently has a consensus target price of $37.78, suggesting a potential upside of 28.23%. Erasca has a consensus target price of $20.11, suggesting a potential upside of 56.26%. Given Erasca's higher possible upside, analysts clearly believe Erasca is more favorable than Maplight Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Maplight Therapeutics
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
3 Strong Buy rating(s)
3.00
Erasca
1 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.60

Maplight Therapeutics' return on equity of 0.00% beat Erasca's return on equity.

Company Net Margins Return on Equity Return on Assets
Maplight TherapeuticsN/A N/A N/A
Erasca N/A -35.31%-29.49%

Erasca is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Maplight TherapeuticsN/AN/A-$161.15M-$40.99N/A
ErascaN/AN/A-$124.55M-$0.93N/A

In the previous week, Erasca had 7 more articles in the media than Maplight Therapeutics. MarketBeat recorded 7 mentions for Erasca and 0 mentions for Maplight Therapeutics. Erasca's average media sentiment score of 0.80 beat Maplight Therapeutics' score of -0.63 indicating that Erasca is being referred to more favorably in the news media.

Company Overall Sentiment
Maplight Therapeutics Negative
Erasca Positive

67.8% of Erasca shares are held by institutional investors. 3.8% of Maplight Therapeutics shares are held by company insiders. Comparatively, 14.2% of Erasca shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Erasca beats Maplight Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Maplight Therapeutics compare to Indivior?

Maplight Therapeutics (NASDAQ:MPLT) and Indivior (NASDAQ:INDV) are both pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, valuation, profitability and risk.

Maplight Therapeutics presently has a consensus price target of $37.78, suggesting a potential upside of 28.23%. Indivior has a consensus price target of $39.33, suggesting a potential upside of 5.20%. Given Maplight Therapeutics' higher possible upside, equities research analysts clearly believe Maplight Therapeutics is more favorable than Indivior.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Maplight Therapeutics
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
3 Strong Buy rating(s)
3.00
Indivior
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.00

Indivior has higher revenue and earnings than Maplight Therapeutics. Maplight Therapeutics is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Maplight TherapeuticsN/AN/A-$161.15M-$40.99N/A
Indivior$1.24B3.68$210M$1.9519.17

Indivior has a net margin of 19.44% compared to Maplight Therapeutics' net margin of 0.00%. Maplight Therapeutics' return on equity of 0.00% beat Indivior's return on equity.

Company Net Margins Return on Equity Return on Assets
Maplight TherapeuticsN/A N/A N/A
Indivior 19.44%-219.26%29.40%

60.3% of Indivior shares are held by institutional investors. 3.8% of Maplight Therapeutics shares are held by insiders. Comparatively, 0.7% of Indivior shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Indivior's average media sentiment score of 1.00 beat Maplight Therapeutics' score of -0.63 indicating that Indivior is being referred to more favorably in the news media.

Company Overall Sentiment
Maplight Therapeutics Negative
Indivior Positive

Summary

Indivior beats Maplight Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Maplight Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for MPLT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MPLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MPLT vs. The Competition

Export
MetricMaplight Therapeutics IndustryManufacturing SectorNASDAQ Exchange
Market Cap$1.19B$2.95B$4.26B$11.99B
Dividend YieldN/A15.25%9.68%5.57%
P/E Ratio-0.7213.6121.7323.74
Price / SalesN/A3,113.05161.90107.95
Price / CashN/A26.8546.5137.25
Price / Book2.924.4430.056.78
Net Income-$161.15M-$40.09M$118.48M$337.51M
7 Day Performance-1.01%-1.71%-3.24%-2.72%
1 Month Performance7.52%-0.59%0.54%1.87%
1 Year PerformanceN/A15.72%12.35%26.60%

Maplight Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MPLT
Maplight Therapeutics
3.544 of 5 stars		$29.46
+5.2%		$37.78
+28.2%		N/A$1.19BN/AN/A109
NNNN
Anbio Biotechnology
0.8164 of 5 stars		$28.51
-11.2%		N/AN/A$4.62B$8.65MN/A27
DNTH
Dianthus Therapeutics
3.058 of 5 stars		$84.97
+4.2%		$117.82
+38.7%		+327.1%$4.46B$2.04MN/A80
TWST
Twist Bioscience
1.4372 of 5 stars		$72.33
+3.1%		$58.00
-19.8%		+119.3%$4.37B$376.57MN/A990
ERAS
Erasca
3.3936 of 5 stars		$13.18
-2.2%		$18.75
+42.3%		+648.1%$4.19BN/AN/A120

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:MPLT) was last updated on 6/8/2026 by MarketBeat.com Staff.
From Our Partners
The chokepoint supplier behind SpaceX's $1.75 trillion empire
When Musk laughed and said 'you need transformers to run transformers,' it wasn't a joke - it was a confession...
Behind the Markets | Sponsoredtc pixel
This is the worst news for stocks in 50 years
Goldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...
TradeSmith | Sponsoredtc pixel
$36 million a day says something big is coming
Institutional capital is flowing into one thesis at a rate of $36 million per day - $25,000 every single minut...
Porter & Company | Sponsoredtc pixel
One hidden supplier shipped 5 billion parts to SpaceX
Most investors are focused on the historic $1.75 trillion SpaceX IPO expected around June 30. But there's a le...
Weiss Ratings | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
Have you tried Elon Musk’s 70X AI agent?
Jeff Brown picked Nvidia in 2016 - it's up 25,155% since. He recommended Bitcoin at $240 - it's up 31,219% sin...
Brownstone Research | Sponsoredtc pixel
June 12th. After That, This Is Gone.
A small publicly traded company holds $9 billion in private SpaceX shares from a 2023 Starlink deal - and it's...
StocksToTrade | Sponsoredtc pixel